NASDAQ:MNOV MediciNova (MNOV) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free MNOV Stock Alerts $1.33 -0.01 (-0.75%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$1.33▼$1.3850-Day Range$1.28▼$1.5752-Week Range$1.26▼$2.66Volume9,333 shsAverage Volume53,218 shsMarket Capitalization$65.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get MediciNova alerts: Email Address Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About MediciNova Stock (NASDAQ:MNOV)MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.Read More MNOV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MNOV Stock News HeadlinesApril 21, 2024 | americanbankingnews.comStockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV)April 2, 2024 | globenewswire.comMediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)April 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 27, 2024 | finanznachrichten.deMediciNova, Inc.: MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in JapanMarch 27, 2024 | msn.comPre-market Movers: IBIO, DRCT, NUVB, PAYS, LUXH…March 27, 2024 | marketwatch.comMediciNova Gets Patent in Japan for Multiple Sclerosis-Related TreatmentMarch 27, 2024 | tmcnet.comMediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in JapanMarch 26, 2024 | globenewswire.comMediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in JapanApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 20, 2024 | globenewswire.comMediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis SocietyMarch 20, 2024 | finance.yahoo.comCompanies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In GrowthMarch 12, 2024 | globenewswire.comMediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of ToxicologyFebruary 29, 2024 | finance.yahoo.comMNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers…February 28, 2024 | money.usnews.comMedicinova IncJanuary 17, 2024 | finanznachrichten.deMediciNova, Inc.: MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in ChinaJanuary 17, 2024 | finance.yahoo.comMediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in ChinaDecember 21, 2023 | finance.yahoo.comMediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of ToxicologyDecember 6, 2023 | markets.businessinsider.comMediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in EuropeDecember 6, 2023 | finance.yahoo.comMediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in EuropeNovember 27, 2023 | finance.yahoo.comMNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO…November 22, 2023 | finance.yahoo.comThe past five years for MediciNova (NASDAQ:MNOV) investors has not been profitableNovember 20, 2023 | msn.comWhy Is Neuro-Oncology-Focused MediciNova Stock Trading Higher Today?November 19, 2023 | finance.yahoo.comMediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-OncologyOctober 28, 2023 | benzinga.comMediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of PhenylketonuriaOctober 27, 2023 | finance.yahoo.comMediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of PhenylketonuriaOctober 12, 2023 | finance.yahoo.comWe're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash WiselyOctober 10, 2023 | finance.yahoo.comMediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in CanadaSee More Headlines Receive MNOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MNOV CUSIPN/A CIK1226616 Webmedicinova.com Phone(858) 373-1500Fax858-404-0048Employees13Year Founded2000Profitability EPS (Most Recent Fiscal Year)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,560,000.00 Net MarginsN/A Pretax Margin-856.80% Return on Equity-13.19% Return on Assets-12.50% Debt Debt-to-Equity RatioN/A Current Ratio15.61 Quick Ratio15.61 Sales & Book Value Annual Sales$1 million Price / Sales65.23 Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book1.05Miscellaneous Outstanding Shares49,046,000Free Float40,757,000Market Cap$65.23 million OptionableOptionable Beta0.75 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Yuichi Iwaki M.D. (Age 74)Ph.D., Co-Founder, President, CEO & Executive Director Comp: $933.05kDr. Kazuko Matsuda M.D. (Age 58)M.P.H., Ph.D., Chief Medical Officer & Director Comp: $653.65kMr. Jason J. Kruger CPA (Age 46)CFO & Principal Financial Officer Dr. David H. Crean M.B.A. (Age 59)Ph.D., Chief Business Officer Mr. John O'Neil CPAControllerKey CompetitorsRallybioNASDAQ:RLYBViveon Health AcquisitionNYSE:VHAQCelularityNASDAQ:CELULantern PharmaNASDAQ:LTRNEagle PharmaceuticalsNASDAQ:EGRXView All CompetitorsInstitutional OwnershipBank Julius Baer & Co. Ltd ZurichBought 19,000 shares on 2/2/2024Ownership: 0.039%Simplex Trading LLCBought 700 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions MNOV Stock Analysis - Frequently Asked Questions How have MNOV shares performed in 2024? MediciNova's stock was trading at $1.50 at the start of the year. Since then, MNOV stock has decreased by 11.3% and is now trading at $1.33. View the best growth stocks for 2024 here. When is MediciNova's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our MNOV earnings forecast. How were MediciNova's earnings last quarter? MediciNova, Inc. (NASDAQ:MNOV) posted its quarterly earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.04. What other stocks do shareholders of MediciNova own? Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Dynavax Technologies (DVAX), VBI Vaccines (VBIV), OPKO Health (OPK), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Trevena (TRVN), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX) and CymaBay Therapeutics (CBAY). How do I buy shares of MediciNova? Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MNOV) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
